Brain Cancer

Immunotherapy Improves Survival Despite Brain Metastases

By

Jody A. Charnow

Publish Date September 17, 2020

Immunotherapy improved median overall survival by 7.5 months regardless of what other treatments patients received.

FDA Grants Orphan Drug Status to Berubicin for Malignant Gliomas

By

Brian Park, PharmD

Publish Date June 16, 2020

he designation is supported by data from a phase 1 trial conducted by Reata Pharmaceuticals in 2016. Findings from the study showed 44% of patients treated with berubicin (n=11 out of 25) experienced a statistically significant improvement in progression free survival.

Short Treatment Delays May Not Hamper Survival in Glioblastoma

By

Christina Bennett, MS

Publish Date May 12, 2020

For patients with glioblastoma, short delays in the initiation of chemoradiotherapy after surgery were not linked to worse survival — yet initiation too soon was.

Pediatric Brain Cancer Outcomes Worse for Black, Hispanic Patients

Publish Date May 5, 2020

Disparities for disease severity not seen at diagnosis, meaning postdiagnosis factors may affect outcome

Time to Radiotherapy After Glioblastoma Resection Affects Survival Outcomes

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date April 2, 2020

A large retrospective analysis demonstrated that a delay of 4 to 8 weeks for adjuvant radiotherapy following surgical resection of glioblastoma improved survival.

Brain Cancer Clinical Trials

Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date

[Cancer Management and Research] A review of past and ongoing trials using ipilimumab-nivolumab combination therapy for metastatic renal cell carcinoma.

Call for ‘Challenge Trials’ to Hasten COVID-19 Vaccine Development

Scientists say such ‘human challenge trials’ are of ‘vast importance’ in speeding up the testing of vaccines.

African-American Participation Inadequate in Cancer Drug Trials

Consistent underrepresentation seen in clinical trials evaluating medications across major cancer types.

Palliative Care in Phase 1 Trials is Essential for Patients and Their Caregivers

Structured palliative care can ensure these patients and their caregivers have an optimal experience that does not hinder trial outcomes.

Eligibility Criteria a Significant Barrier to Patient Enrollment in Oncology Clinical Trials

Review of responses to clinical trial prompts within an oncology clinical pathways system identified barriers to increasing patient enrollment in clinical trials.